A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He ...

Al-Aly is a physician and researcher at Washington University in St. Louis and chief of research at the VA Saint Louis Health Care System. At a dinner party recently, someone poured my friend a glass ...

A new review explores how GLP-1 receptor agonists may blunt alcohol and drug reward signals, opening a promising but still unproven path toward repurposed treatments for addiction. Review: The role of ...

How political red tape and a drug company’s thirst for profits limited the reach of a drug that experts believe could have reduced the opioid epidemic’s toll. Credit...Photo illustration by Ben Denzer ...

GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain. Early trials show reductions in alcohol intake, opioid seeking, ...

Remarkable scientific progress over the past five decades has helped us develop knowledge of how drugs of abuse induce pleasure, reinforce use, and lead to the compulsive self-administration we call ...

Researchers believe that GLP-1 drugs act on reward areas of the brain that are responsible for food cravings, making it possible that they silence cravings for addictive substances. The Conversation — ...